CHAPTER 52
Parkinson’s Disease
Lana Hareez, PharmD, BCPS • Antony Q. Pham, PharmD, BCPS
More than 1 million people in the United States are affected by Parkinson’s disease (PD; Marras & Tanner, 2004). PD is a neurodegenerative disease with no known cause or cure. It is essential to recognize that “parkinsonism” refers nonspecifically to syndromes of akinetic rigidity. Several different kinds of parkinsonism can be mentioned: postencephalic, arteriosclerotic, posttraumatic, secondary to medications, atrophic encephalopathic, and as part of a wider involvement of the nervous system in olivopontocerebellar atrophy and other neurodegenerative diseases. Idiopathic PD is the most common form of parkinsonism and is the primary focus of this chapter.
James Parkinson’s “An Essay on the Shaking Palsy” in 1817 first described features of PD. His accounts of six patients were a remarkably accurate assessment of the clinical features of the disease, which now bears his name. PD is referred to as a distinct clinicopathologic disorder classically defined by three cardinal features: resting tremor, rigidity, and bradykinesia. Postural instability, often considered a fourth cardinal sign, occurs later in the course of the disease and is not included in most diagnostic criteria (American Medical Directors Association [AMDA] Guidelines, 2010).
ANATOMY, PHYSIOLOGY, AND PATHOLOGY
The primary neurochemical lesion of PD results from the deficiency of dopamine in the basal ganglia. This depletion of dopamine causes degeneration of neurons, leading to disruption of nerve connections to the thalamus and motor cortex. Other monoaminergic systems besides the dopaminergic system can be affected in PD. Histochemical studies confirm degeneration of both the noradrenergic locus coeruleus system and the serotonergic raphe nuclear groups. The cholinergic system is affected as well, most notably with the nucleus basalis of Meynert (Schapira et al., 2006). It is estimated that the loss of 70% or greater of substantia nigra neurons and a loss of 80% or more of striatal dopamine are necessary to have the clinical symptoms of PD. This suggests a longer presymptomatic phase during which selective neuronal cell death progresses.
The cause of PD is ultimately unknown. The role of genetics in the disease has been debated for many years and remains controversial. Studies of monozygotic and dizygotic twins with an index case of PD have been variably interpreted and suggest that genetics may not bear a strong influence on the cause of PD (Hardy, Cai, Cookson, Gwinn-Hardy, & Singleton, 2006).
However, PET studies have shown that asymptomatic twins of parkinsonian patients commonly have abnormalities of striatal dopamine uptake. If these findings are valid, a genetic predisposition for PD would be supported. Attempts to identify the gene or genes involved in the development of PD are in progress. One large family with parkinsonism, the Contursi kindred, has been well studied for several years (Golbe, Di Iorio, Bonavita, Miller, & Duvoisin, 1990). In 1996, researchers announced that the region of the chromosome responsible for the genetic transmission of parkinsonism in the Contursi family was found, probably with an autosomal dominant type of genetic inheritance. However, this chromosome area has not been linked to all cases of familial PD (Polymeropoulos et al., 1996).
Many researchers have focused their interest on the possibility that PD may be caused, at least in part, by environmental factors. This fact was supported by the development of parkinsonian symptoms in several young people after they used an illegal drug (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]) related to the narcotic meperidine. A single dose of this compound can cause selective destruction of the nigrostriatal dopaminergic neurons (Langston, Ballard, Tetrud, & Irwin, 1983). It is thought that the sequence of events involves MPTP successive oxidation by monoamine oxidase B (MAO-B) to the dihydropyridinium and pyridinium ion derivatives. The latter compound (1-methyl-4-phenylpyridium; MPP+) is actively and specifically accumulated in the dopaminergic terminals by the dopamine uptake system. It is also accumulated nonspecifically by mitochondria and acts as a reversible inhibitor of mitochondrial oxidative phosphorylation at the level of NADH dehydrogenase (Complex I). It appears that the resultant loss of ATP-generating capacity, with consequent changes in the ability to maintain membrane potentials, calcium ion homeostasis, and consequent free radical generation, may be sufficient to cause neuronal degeneration (Taipton, McCrodden, & Sullivan, 1993).
There is no investigation that supports a viral etiology for PD. After the pandemic of encephalitis lethargica (1919–1926), many cases of parkinsonism were observed but no definite causal relation was established implicating a specific virus. Transient parkinsonian features may occur during the acute or convalescent phases of a variety of viral encephalitides, including measles, Japanese B, and western equine. Rarely, parkinsonism may remain as a permanent sequela (Schapira et al., 1992).
Unrecognized environmental toxins structurally similar to MPTP may play a role in the etiology of PD. The major culprits are suspected to be industrial chemicals, herbicides, and pesticides in well water. Exposure to manganese dust or carbon disulfide causes parkinsonian symptoms and the diagnosis is suggested by an accurate occupational history. Parkinsonism sometimes occurs as a result of severe carbon monoxide poisoning.
Endogenous toxins may also be responsible. In particular, the normal neurotransmitter dopamine readily oxidizes to produce free radicals that destroy the dopaminergic nerves. Although the precise role of dopamine itself remains unclear, the evidence relating PD to damage by free radicals remains compelling. This evidence includes increased iron levels, increased lipid peroxidation, decreased peroxidase and catalase levels, increased superoxide dismutase levels, and decreased glutathione levels.
NEUROANATOMY
Movement disorders result from disease of the basal ganglia. This consists of the caudate and the putamen (together called the striatum), the internal and external segments of the globus pallidus, the subthalamic nucleus (STN), and the substantia nigra. Cortically initiated movements are facilitated and competing movements are inhibited through the influence of the basal ganglia.
The activity of the output structures of the basal ganglia (the internal segment of the globus pallidus and the pars reticulata of the substantia nigra) is controlled by two opposing striatal pathways. The direct pathway consists of the striatal projections to the substantia nigra pars reticulata and the globus pallidus interna (GPi). This pathway is gamma-aminobutyric acid (GABA)-ergic and inhibitory, expressed mainly on the dopamine D1 receptor. This direct route then functions to facilitate thalamocortical projections that reinforce cortically initiated movement. An alternative polysynaptic (indirect) pathway involves striatal GABA-ergic, inhibitory neurons that express the dopamine D2 receptors and project to the globus pallidus externa, which has an inhibitory effect on the STN (Hutchinson, Levy, Dostrovsky, Lozano, & Lang, 1997). This nucleus has excitatory glutamatergic feedback on the globus pallidus externa and excitatory glutamatergic input on the substantia nigra pars reticulata and the GPi. The final effect of the indirect pathway is that striatal activity would lead to disinhibition of the STN, which in turn leads to higher activity of the neurons in the basal ganglia output nuclei and a stronger inhibition of their targets.
A balance between direct and indirect pathways is crucial for the normal functioning of the basal ganglia-thalamocortical circuits. It is also important to the balance among dopamine receptors in each pathway because dopamine has opposing effects on the two striatal output pathways—a stimulatory effect on the D1 receptor-containing direct pathway and a suppressory effect on the D2 receptor-containing indirect pathway (Groenewegen, 1997).
In PD, loss of dopaminergic cells in the substantia nigra leads to striatal dopamine depletion. This depletion results in decreased activity of the direct pathway and increased activity of the indirect pathway. This ultimately causes a reduced thalamic excitation of the motor cortex and loss of facilitation of cortically initiated movement. The two striatal output pathways are out of balance and act in the same direction. This may explain, at least in part, the hypokinesia characteristic of PD. The resting tremor of PD is less readily explained by the model but may result from effects on cholinergic interneurons in the striatum (Schapira et al., 2006).
EPIDEMIOLOGY
PD usually commences in middle or late life and leads to progressive disability with time. There are approximately 5 million people with PD worldwide, depending on the diagnostic criteria used (Scherzer et al., 2007). One study compared nondemented elderly people in the same community with PD patients and found a two- to fivefold increased risk of death. The risk is strongly related to the presence of severe extrapyramidal symptoms, especially bradykinesia (Louis, Marder, Cote, Tang, & Mayeux, 1997).
There is some discrepancy in the ethnic and sex distribution of PD. Some researchers believe the disease occurs more commonly in men than women; others insist it has an equal sex distribution. Although the disease occurs in all ethnic groups, most reports show that PD is more common among Whites than non-Whites. The prevalence is approximately 1 per 100 and 2.5 per 100 for people older than 65 and 80 years, respectively (Van Den Eeden et al., 2003). The disease is uncommon among the young, although about 5% of PD patients develop the illness before the age of 40 years.
HISTORY AND PHYSICAL EXAMINATION
So gradual and insidious is the onset of PD that patients can rarely pinpoint the precise date it began. Initial manifestations are often noted by someone other than the patient. Usually it is someone close to the patient who notices some subtle changes, perhaps in posture or manner of walking or moving. Eventually the patient becomes aware that something is indeed wrong. There may be persistent tiredness, minor aches and pains, or a vague sense of malaise. Perhaps the patient feels a lack of energy or a sense of nervousness and irritability. Performance on the job may be declining for no apparent reason. The patient may notice that things that were formerly performed easily, without a thought, now require conscious effort.
Diagnostic mistakes can occur early in the course of the disease as health care providers differentiate initial symptoms. The diagnosis can be made with certainty only when three cardinal signs are present: resting tremor, rigidity, and bradykinesia.
Resting tremor is usually the first cardinal sign to appear in PD (70% of presenting patients; Findley, Gresty, & Halmagyi, 1981). This tremor is relatively slow (4–6 Hz) and can be appreciated when a limb is supported or relaxed (arm resting in lap or hanging by the side). Resting tremors are normally abolished by complete relaxation (during sleep) or by voluntary movement of the limb (Nutt, 1997). The tremor generally begins intermittently in one hand, to-and-fro flexion movement of the wrist, hand, thumb, and fingers that is most apparent when the patient sits comfortably. The cupped hand’s appearance of shaking pills gave rise to the name “pill-rolling” tremor (Friedman, 1994). Then from one hand, the tremor spreads to the ipsilateral foot, subsequently to the contralateral limbs, and perhaps to the tongue and jaw. It is important to distinguish the Parkinson’s resting tremor, which is frequently asymmetrical, from the essential tremor, which is symmetrical and commonly affects upper extremities, head, and voice, but rarely the legs. Patients with essential tremors display large and irregular (tremorous) handwriting while patients with other parkinsonism display rather small (micrographia) handwriting.
Rigidity, defined as an increase in resistance to passive movement, is a common clinical feature that accounts for the flexed posture of many patients. Rigidity also begins unilaterally (typically on the same side as the initial tremor) but eventually becomes contralateral over time. On examination, rigidity can be tested by manipulating the patient’s limbs. Cogwheel rigidity (ratchet resistance to full-range limb movements) as well as lead-pipe rigidity (smooth resistance throughout entire range of motion) are appreciable in approximately 90% of PD patients (Scott, Brody, Schwab, & Cooper, 1970).
The most disabling cardinal feature of PD is likely bradykinesia. Bradykinesia is a slowness of voluntary movement associated with a reduction in coordinated automatic movements such as the swinging of both arms when walking. Patients with bradykinesia have difficulty initiating voluntary movement and may appear weak or uncoordinated. Other findings can include mask-like facies with widened palpebral fissures and infrequent blinking. There may be blepharoclonus (fluttering of the closed eyelids), blepharospasm (involuntary closure of the eyelids), and drooling of saliva from the mouth. Patients have difficulty rising from bed or an easy chair and tend to assume a flexed posture when standing upright.
Patients with postural instability have impaired balance and have a greater tendency for falls. The other three cardinal symptoms are likely already established, as postural instability does not appear until the later stages of PD.
Patients with PD can have other motor impairments in addition to the cardinal symptoms. Patients may have difficulty turning over in bed. This difficulty in turning when lying flat is the result of an inability to execute the sequence of axial movements required to achieve the task. This disability becomes more prominent with longer disease duration (Steiger, Thompson, & Marsden, 1996). Walking can be difficult to initiate and patients may have to lean forward increasingly until they can advance. The tension reflexes are unaltered and the plantar responses are flexor. Repetitive tapping over the glabella produces a sustained blink response (Myerson’s sign), in contrast to the response of normal subjects. Other findings include impaired craniofacial movements, psychomotor retardation, fatigue, sleep disorder, blurred vision, speech impairment, and unilateral findings. This presentation may lead to the misdiagnosis of depression or stroke.
Fifty percent of patients presenting with tremor do not have PD and a broader differential diagnosis must be considered. The history should focus on the development of neurologic symptoms, depression, other concurrent medical illnesses (e.g., hypothyroidism), medications, injuries (e.g., falls), and occupational hazards. Drug-induced disease should be ruled out by the elimination of offending drugs such as neuroleptics, antiemetics (e.g., metoclopramide), and antihypertensives (e.g., reserpine, methyldopa). The physical examination should include a thorough mental status and neurologic examination. Passive movement of the wrist or elbow may reveal cogwheel rigidity.
The gait features marche a petit pas (characterized by short steps with a tendency to accelerate), shuffling, lack of arm swing, and the turning of the body en bloc. Speech is often soft and monotonal, and it may be inaudible. Autonomic insufficiency may result in constipation, impotence, and orthostatic hypotension.
Nonmotor symptoms can also be debilitating in PD. Mental changes such as dementia occur in about 15% to 20% of people with PD, and in 40% of patients older than 70 years (Hussl, Seppi, & Poewe, 2013). The so-called subcortical dementia of PD is distinguished from the cortical dementia of Alzheimer’s disease. Depression affects almost 50% of PD patients and psychosis is present in at least 10%. Visual hallucinations, delusions, and chronic confusion are the most common psychotic features. This psychosis is most often attributable to a combination of dementia, antiparkinsonian medications, and the toxic-metabolic encephalopathy from other illnesses (Politis et al., 2010).
DIAGNOSTIC STUDIES
Early and accurate detection of PD is useful from the viewpoint of addressing patients’ future health. The majority of the tests and possible early markers for idiopathic PD are still under research. As a result, the clinical diagnosis relies heavily on a thorough patient history, and physical and neurological examination. Blood tests and computerized scans are useful to rule out other etiologies, but are yet to be revealed in the diagnosis of PD. According to the AMDA Guidelines in 2010, all three cardinal symptoms (resting tremor, bradykinesia, and rigidity) along with an asymmetric onset must all be present to maintain a definitive diagnosis of PD. In addition, a strong response to dopaminergic therapy plays a supportive role in confirming the diagnosis.
Brain Imaging
In single-photon emission computed tomographic imaging (SPECT), radioactive iodine (123I Beta-CIT) is used to label dopamine transporters and is therefore a marker of the neurons that degenerate in PD. SPECT with 123I Beta-CIT showed that the radioactivity in striatal regions in healthy subjects increased during a 2-day imaging study, whereas that in parkinsonian patients peaked earlier at lower levels than in healthy subjects. Kinetic analysis of the radioactivity in plasma and the brain suggested that this decrease was the result of an approximately 65% loss of target sites in patients versus healthy subjects; greater losses occurred in the putamen than in the caudate. These preliminary results suggest that 123I Beta-CIT is a marker for the loss of striatal dopamine terminals in patients with PD and may be useful for early diagnosis of the disorder, monitoring the progression of the disease, and distinguishing the idiopathic disorder from other parkinsonian syndromes with more widespread pathology (Olanow & Schapira, 2013).
Magnetic Resonance Imaging
MRI with high field strength can be performed to rule out structural brain abnormalities and exclude findings of atypical parkinsonism. Neuroimaging is considered nondiagnostic and further studies must be performed to explore its diagnostic abilities (Vaillancourt et al., 2009).
Blood Analysis
Parker, Boyson, and Parks (1989) reported a reduction of mitochondrial complex I (NADH ubiquinone oxidoreductase) in the platelets of patients with idiopathic parkinsonism. Others have reported reduced S-oxidation capacity in patients with idiopathic parkinsonism. There is also an increase in the ratio of cysteine to sulfate, and this may impair the body’s ability to metabolize environmental toxins.
MAO-B in platelets deaminates endogenous dopamine. It may also activate environmental protoxins. The oxidation of dopamine may produce increased free radicals, which in turn may damage dopaminergic neurons. Researchers have found a highly significant increase in the generation of oxygen free radicals (in leukocytes) in idiopathic parkinsonism. Malondialdehyde is a product of tissue injury by lipid peroxidation of membrane phospholipids, and levels are elevated in the serum of patients with idiopathic PD.
Physiologic Testing
Long-latency stretch reflexes, increased latency of the visual evoked potential, and a deficit in olfactory discrimination have been found in patients with PD. Lewy bodies are not limited to the substantia nigra in PD; they can be found in sympathetic ganglia and in the mesenteric plexi of the whole gastrointestinal tract, particularly the lower esophagus. This may lead to a possible diagnostic evaluation for idiopathic parkinsonism through biopsy of a more accessible location and may be the subject of further exploration.
DIFFERENTIAL DIAGNOSIS
Multiple neurologic and psychiatric disorders, some associated with exposure to medications or toxins as well as other clinical conditions, can mimic and share similar features with idiopathic PD. Table 52.1 lists the most commonly prescribed medications that can cause secondary parkinsonism. Table 52.2 summarizes other causes of secondary parkinsonism and lists the neurologic system degenerations that may have parkinsonism as a major component of the clinical picture. It is important to differentiate between the various parkinsonian syndromes because there is prognostic significance. For instance, idiopathic PD responds to levodopa, but in other forms of parkinsonism levodopa is less beneficial and may produce major side effects (Merello, Nouzeilles, Arce, & Leiguarda, 2002).
All antipsychotic (neuroleptics) medications. First-generation > second-generation
Phenothiazines (prochlorperazine, promethazine, chlorpromazine)
Butyrophenones (haloperidol, fentanyl)
Thioxanthines (thiothixene)
Antiemetics
Metoclopramide
Droperidol
Lithium
Antihypertensives
Reserpine
Methyldopa (Aldomet)
Antidepressant
Amoxapine
CAUSE OR NEUROLOGIC DISORDER | FEATURES DIFFERENTIATING FROM PD |
Encephalitis | History of pupillary and extraocular abnormalities, oculogyric crises, other neurologic signs. |
Head trauma | History of boxing, other neurologic signs, cerebellar and corticospinal signs. |
Toxins | History of exposure to carbon monoxide, carbon disulfide, cyanide, manganese, mercury, methanol, or MPTP (neurotoxic meperidine analog used by drug addicts). |
Normal-pressure hydrocephalus | Urinary urgency, gait disorder, but with relatively intact arm swing; CT or MRI. |
Essential senile tremor | Positive family history; present during maintenance of posture (postural tremor) and aggravated by stressful situations; flexion/extension type; decreases tremor with ethanol; treatment: propranolol, primidone. |
Atherosclerotic parkinsonism | Akinetic rigid state without tremor; corticospinal signs. Diagnosed by CT, MRI. PD “from waist down.” |
Striatonigral degeneration; Shy Drager syndrome and olivopontocerebellar atrophy | Autonomic dysfunction (particularly orthostatic hypotension), cerebellar ataxia, corticospinal tract signs. |
Progressive supranuclear palsy | Paresis of voluntary vertical gaze (particularly downward gaze). pseudobulbar palsy; marked postural instability with relatively preserved locomotion. |
Corticobasal ganglionic degeneration | Asymmetric in onset; aphasia and apraxia without memory dysfunction. Resting tremor does not occur; corticospinal tract signs and limb dystonia are common; gaze palsies. |
Alzheimer’s disease | Early and prominent dementia preceding motor abnormalities; aphasia, apraxia, agnosia; less depression associated. |
Creutzfelt—Jakob disease | Rapidly progressive dementia; myoclonus, ataxia, pyramidal signs, visual disturbance. Electroencephalogram is characteristic. |
Rigid Huntington’s disease | Family history of Huntington’s disease. |
Depression | Abnormal affect without rigidity or resting tremors. Good response to antidepressant therapy. |
Diffuse Lewy body disease | Cortical dementia, aphasia, apraxia; labile affect. |